China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. It offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. The company also provides bone peptide, oxytocin, heparin sodium, and posterior pituitary injection produ… Read more
China Resources Boya Bio pharmaceutical Group Co Ltd - Asset Resilience Ratio
China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has an Asset Resilience Ratio of 26.98% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down China Resources Boya Bio pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.35 Billion | 26.98% |
| Total Liquid Assets | CN¥2.35 Billion | 26.98% |
Asset Resilience Insights
- Very High Liquidity: China Resources Boya Bio pharmaceutical Group Co Ltd maintains exceptional liquid asset reserves at 26.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
China Resources Boya Bio pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare China Resources Boya Bio pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for China Resources Boya Bio pharmaceutical Group Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for China Resources Boya Bio pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.18% | CN¥2.20 Billion | CN¥8.40 Billion | -16.77pp |
| 2023-12-31 | 42.95% | CN¥3.36 Billion | CN¥7.83 Billion | +3.19pp |
| 2022-12-31 | 39.76% | CN¥3.19 Billion | CN¥8.03 Billion | +4.33pp |
| 2021-12-31 | 35.42% | CN¥2.70 Billion | CN¥7.62 Billion | +33.36pp |
| 2016-12-31 | 2.07% | CN¥50.00 Million | CN¥2.42 Billion | +1.15pp |
| 2015-12-31 | 0.91% | CN¥20.00 Million | CN¥2.19 Billion | -- |